Cinda Securities(SH:601059) Sou Hu Cai Jing·2025-07-30 06:13Group 1 - The core viewpoint is that the pharmaceutical and biotechnology industry is expected to benefit from the recent outbreak of Chikungunya fever, with a gradual recovery in vaccine sector performance and potential valuation adjustments due to innovation attributes [1] - The pharmacy sector is exploring new business models in the context of medical insurance reforms, with non-pharmaceutical products emerging as a potential breakthrough direction [1] - The diagnostics sector is anticipated to improve due to the digestion of pandemic-related baselines and new demand arising from the current health landscape [1] Group 2 - The medium to long-term focus is on "innovation + AI healthcare + recovery," with innovative drugs and medical devices receiving clear support from the National Healthcare Security Administration, emphasizing differentiated innovation [1] - AI healthcare is gaining attention due to the World Artificial Intelligence Conference, with focus areas including diagnostic paradigms and drug development [1] - Recovery lines include a rebound in medical equipment procurement, as well as a restoration of demand in CXO and upstream life sciences [1] Group 3 - The Guotai Innovation Drug ETF (517110) tracks the SHS Innovation Drug Index (931409), which selects listed companies involved in new drug research, production, and sales from the Shanghai, Shenzhen, and Hong Kong markets to reflect the overall performance of innovative pharmaceutical companies [1] - Investors without stock accounts can consider the Guotai CSI Hong Kong-Shenzhen Innovation Drug Industry ETF Initiation Link C (014118) and Link A (014117) [1]